MCP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement
PARSIPPANY, NJ February 24, 2011 — MCP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectable products announced today that it has entered into a multi‐year contract manufacturing agreement with an undisclosed biotechnology company. MCP will be responsible for manufacturing and supply of an approved therapy used in cancer patients.
Stuart Hinchen, president and co-founder of MCP stated “We recognize that being selected to produce this crucial drug demonstrates our ability to meet critical marketplace needs.
MCP was able to achieve the rigorous timelines required to manufacture this drug through a quality-driven, experienced staff and a customer‐centric approach. Additionally, our record of cGMP compliance, coupled with our experience in manufacturing site transfers put us in the position to serve this important customer.”
Hinchen also noted, “This will be the second multi-year contract MCP has entered during the last two months. These agreements are examples of how our approach to ongoing investment in our people and facilities allow us to focus on customer needs which results in rising, sustainable growth. Our Rochester, Michigan manufacturing site has a solid history of successful partnerships, manufacturing both clinical and commercial products.”
About MCP Pharmaceuticals, LLC
MCP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile injectables, biologics, vaccines, ophthalmics and otics for large and small pharmaceutical and biotech organizations.
MCP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse. The production facility utilizes three high-speed filling lines, four lyophilizers and a clinical fill line. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development.
MCP has the capability to manufacture small-scale clinical through large-scale commercial products. MCP employs more than 330 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas. For more information, please visit jhppharma.com.
Additional Press Releases
 |
MCP Pharmaceuticals Enters Agreement To Produce Life-Saving Drug Webpage | PDF Format |
|
MCP Pharmaceuticals Announces Chief Executive Officer Succession Webpage | PDF Format |
|
MCP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin® Webpage | PDF Format |
|
MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement Webpage | PDF Format |
|
MCP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement Webpage | PDF Format |
|
MCP Pharmaceuticals & Putney Inc. Announce Multi-Year Contract Manufacturing Agreement Webpage | PDF Format |
|
MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement Webpage | PDF Format |
|
MCP Pharmaceuticals Announces Successful Completion of FDA and EMEA GMP Audits Webpage | PDF Format |
|
MCP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds Webpage | PDF Format |
|
MCP Pharmaceuticals & SpePharm complete purchase of Dantrium® (dantrolene sodium) Webpage | PDF Format |
|
King Pharmaceuticals Completes Sale Of Rochester, Michigan Manufacturing Facility To MCP Pharmaceuticals Webpage | PDF Format |
Return To Press & News »
